News

Owens Corning Earnings Preview: Analysts Adjust Expectations

Owens Corning Earnings Preview: Analysts Adjust Expectations

Owens Corning Set to Announce Earnings Soon

Owens Corning (NYSE: OC) is gearing up to share its fourth-quarter financial results shortly after the closing bell. Investors and analysts alike are watching closely, as the company looks to provide insights into its performance and future outlook.

Analysts Project Earnings and Revenue Changes

Current market expectations indicate that Owens Corning will report quarterly earnings amounting to $2.91 per share. This marks a decline from the $3.21 per share noted in the same quarter last year. On a positive note, the company anticipates revenue to rise to approximately $2.77 billion, a considerable increase from the $2.3 billion reported in the previous year.

Strategic Business Moves

Recently, Owens Corning has made significant strategic decisions to enhance its position in the market. On February 14, the company announced an agreement to sell its glass reinforcements business to Praana Group for an enterprise value of $755 million. This move could allow Owens Corning to refine its focus on core operations and invest more into growth areas.

Market Responses to Recent Developments

The market has responded somewhat adversely to these developments, with Owens Corning shares falling by 1.2%, bringing the closing price down to $172.10 recently. Market analysts are keenly evaluating these trends as they provide insights into the company's current standing.

Current Analyst Ratings and Predictions

As earnings season approaches, let’s examine the recent ratings by some of the most accurate analysts following Owens Corning:

  • Loop Capital's Garik Shmois has retained a Buy rating, adjusting the price target down from $215 to $210, reflecting his 70% accuracy rate.
  • Citigroup’s Paul Lejuez also maintained a Buy rating but lowered his price target from $212 to $207, with an accuracy rate of 65%.
  • In a more favorable update, Barclays analyst Matthew Bouley upgraded the stock from Equal-Weight to Overweight, increasing the price target significantly from $192 to $245. He holds a commendable accuracy rate of 72%.
  • RBC Capital's Mike Dahl has kept his Outperform rating intact and raised the price target from $213 to $217, boasting a 73% accuracy rate.
  • Finally, UBS analyst John Lovallo maintained a Buy rating and increased the price target from $197 to $218, having an accuracy rate of 69%.

Insights Into Owning OC Stock

Are you contemplating adding OC stock to your investment portfolio? Analysts are currently optimistic about its growth trajectory and have shared their insights on the potential opportunities this stock may present in the near future.

Future Expectations for Owens Corning

As Owens Corning advances towards its earnings announcement, market watchers are eager to see how the company’s evolving strategies and recent decisions will influence future earnings and overall business performance. With a mix of analyst ratings and market reactions, the upcoming earnings call promises to shed light on the company's future endeavors.

Frequently Asked Questions

What are the expected earnings for Owens Corning?

Analysts predict Owens Corning will report earnings of $2.91 per share for the upcoming quarter.

How did Owens Corning's revenue perform last year?

The company reported revenue of $2.3 billion in the same quarter last year, with expectations to increase this to $2.77 billion.

What strategic move did Owens Corning recently make?

Owens Corning announced the sale of its glass reinforcements business to Praana Group for $755 million.

How have analysts rated OWens Corning stock?

Analysts have rated Owens Corning stock with a mix of Buy and Outperform ratings, reflecting a positive outlook.

What was the recent market response to Owens Corning's shares?

Recently, Owens Corning's shares dropped by 1.2%, closing at $172.10.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 79

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 189

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 85

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 129

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 389

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 0

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 166

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading

Top 5 Most Recently Viewed Articles

Vor Bio's Exploration of Strategic Alternatives for Growth

Updated Category News Views 213

Vor Bio Announces Exploration of Strategic Alternatives Today, Vor Bio, a clinical-stage cell and genome engineering company, has taken significant steps to enhance shareholder value. The decision comes at a time when the clinical data from its major programs suggests that reevaluating its approach could be beneficial in the face of challenging fundraising conditions....

Continue Reading
Kraig Biocraft Achieves Record Production in Spider Silk Fibers

Updated Category News Views 56

Kraig Biocraft Laboratories' Milestone in Spider Silk Production Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneering firm renowned for its innovative developments in spider silk-based fibers, is thrilled to share the successful conclusion of its fourth production cycle for the year. This cycle represents a remarkable achievement, showcasing record-breaking...

Continue Reading
Gen X Faces Retirement Challenges: Understanding the Crisis

Updated Category News Views 282

Gen X’s Coming Retirement Crunch Gen X—often called the “sandwich generation”—is being pulled in two directions at once and edging toward a retirement problem many don’t fully see. With money, time, and attention split between family and work, long-term savings can drift to the back burner. The worry isn’t abstract; it’s about whether the money will be...

Continue Reading
Luxurious Villa Spectre: A $55 Million Icon of Elegance

Updated Category News Views 342

Villa Spectre: A $55 Million Marvel of Luxury Living Villa Spectre has recently captured the spotlight as the highest-priced sale in the area, setting a remarkable benchmark in luxury real estate. This impressive estate was sold for $55,000,000, showcasing the allure and opulence that the elite have come to expect from high-end properties. A Visionary Creation Designed by...

Continue Reading
Mosaic Minerals Shifts Focus to Gold with Amanda Acquisition

Updated Category News Views 333

Mosaic Minerals Re-prioritizes Focus on Gold Exploration Mosaic Minerals Corporation (CSE: MOC) is making a strategic pivot in its exploration efforts. The company has announced the cessation of its lithium exploration initiatives, particularly those in Jamésie, Quebec. Instead, Mosaic is setting its sights on more promising ventures in gold and nickel, specifically...

Continue Reading